Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron concludes promising fatty liver disease clinical study

The company will report top line clinical trial results in Q1 2018.
model of a liver
The study enrolled 133 patients

Immuron Ltd (ASX:IMC, NASDAQ:IMRN) has concluded the phase II study of IMM‐124E for the treatment of NASH (non-alcoholic steatohepatitis), with the results expected in Q1 2018.

NASH is also known as non-alcoholic fatty liver disease.

The last patient in the clinical study conducted the final scheduled visit on October 9, following a 28‐week study period. The study enrolled a total of 133 patients with biopsy‐proven NASH.

On October 18, the study site conducted its close‐out visit.

This effectively concludes patient dosing and research activities at all study sites for the Phase II study. 

Immuron will report its top line clinical trial results in Q1 of calendar year 2018, once all data is finalised and reviewed by the company and its scientific advisory board.

Once reported, Immuron will continue its partnering and business development efforts to reach the next phase of clinical studies.

In July 2017, the company revealed interim analysis results, in which IMM‐124 demonstrated a statistically‐significant reduction in two enzymes found in the liver, compared to the placebo.

These preliminary results suggested a reduction in liver injury over the duration of treatment compared to the placebo.





Register here to be notified of future IMC Company articles
View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017
Newswire
May 27 2016

Related Articles

Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 06 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
Patient undergoing radiotherapy
August 02 2017
Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use